203 related articles for article (PubMed ID: 31792304)
1. Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
Statler AB; Hobbs BP; Wei W; Gupta A; Blake CN; Nahleh ZA
Sci Rep; 2019 Dec; 9(1):18126. PubMed ID: 31792304
[TBL] [Abstract][Full Text] [Related]
2. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.
Swallow E; Zhang J; Thomason D; Tan RD; Kageleiry A; Signorovitch J
Curr Med Res Opin; 2014 Aug; 30(8):1537-45. PubMed ID: 24669852
[TBL] [Abstract][Full Text] [Related]
3. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
4. Effect of hormone therapy on long-term outcomes of patients with human epidermal growth factor receptor 2- and hormone receptor-positive metastatic breast cancer: real world experience in China.
Du F; Yuan P; Wang JY; Ma F; Fan Y; Luo Y; Xu BH
Asian Pac J Cancer Prev; 2015; 16(3):903-7. PubMed ID: 25735380
[TBL] [Abstract][Full Text] [Related]
5. Clinical Outcomes, Treatment Patterns, and Health Resource Utilization Among Metastatic Breast Cancer Patients with Germline BRCA1/2 Mutation: A Real-World Retrospective Study.
Quek RGW; Mardekian J
Adv Ther; 2019 Mar; 36(3):708-720. PubMed ID: 30656571
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic outcomes by first-line treatment among women with HR+/HER2- metastatic breast cancer in a large US health plan database.
Burton T; Byfield SD; Smith GL; Zanotti G; Bell TJ; Perkins JJ; Horblyuk R; Teitelbaum A
Curr Med Res Opin; 2016 Aug; 32(8):1417-23. PubMed ID: 27074160
[TBL] [Abstract][Full Text] [Related]
7. Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer.
Park HS; Sohn J; Kim SI; Park S; Park HS; Gho SG; Chung HC; Paik S; Kim GM
Breast Cancer Res Treat; 2017 Jun; 163(2):255-262. PubMed ID: 28243895
[TBL] [Abstract][Full Text] [Related]
8. Elucidating Determinants of Survival Disparities Among a Real-world Cohort of Metastatic Breast Cancer Patients: A National Cancer Database Analysis.
Statler AB; Wei W; Gupta A; Blake CN; Hobbs BP; Nahleh ZA
Clin Breast Cancer; 2020 Oct; 20(5):e625-e650. PubMed ID: 32434711
[TBL] [Abstract][Full Text] [Related]
9. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
10. Patient-reported Quality of Life and Treatment Satisfaction in Patients With HR
Wood R; Mitra D; de Courcy J; Iyer S
Clin Ther; 2017 Aug; 39(8):1719-1728. PubMed ID: 28751098
[TBL] [Abstract][Full Text] [Related]
11. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and survival in metastatic breast cancer patients by tumor characteristics.
Hao Y; Meyer N; Song X; Shi N; Johnson W; Juneau P; Yardley DA; Willemann Rogerio J
Curr Med Res Opin; 2015 Feb; 31(2):275-88. PubMed ID: 25365467
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).
Macalalad AR; Hao Y; Lin PL; Signorovitch JE; Wu EQ; Ohashi E; Zhou Z; Kelley C
Curr Med Res Opin; 2015 Feb; 31(2):263-73. PubMed ID: 25350226
[TBL] [Abstract][Full Text] [Related]
14. Second-Line Treatment of Her2-Positive Metastatic Breast Cancer: Trastuzumab beyond Progression or Lapatinib? A Population Based Cohort Study.
Hammerman A; Greenberg-Dotan S; Feldhamer I; Bitterman H; Yerushalmi R
PLoS One; 2015; 10(9):e0138229. PubMed ID: 26375590
[TBL] [Abstract][Full Text] [Related]
15. Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database.
Kaczmarek E; Saint-Martin C; Pierga JY; Brain E; Rouzier R; Savignoni A; Mouret-Fourme E; Dieras V; Piot I; Dubot C; Carton M; Lerebours F
Breast Cancer Res Treat; 2019 Dec; 178(3):505-512. PubMed ID: 31486993
[TBL] [Abstract][Full Text] [Related]
16. Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy.
Fu F; Yu L; Zeng B; Chen M; Guo W; Chen L; Lin Y; Hou J; Li J; Li Y; Li S; Chen X; Zhang W; Jin X; Cai W; Zhang K; Chen H; Qiu Y; Nie Q; Wang C; Jacobs L
JAMA Netw Open; 2022 Feb; 5(2):e2145934. PubMed ID: 35166783
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns, survival and economic outcomes in Medicare-enrolled, older patients with HR+/HER2- metastatic breast cancer.
Goyal RK; Carter GC; Nagar SP; Smyth EN; Price GL; Huang YJ; Li L; Davis KL; Kaye JA
Curr Med Res Opin; 2019 Oct; 35(10):1699-1710. PubMed ID: 31060392
[No Abstract] [Full Text] [Related]
18. Real-world Data on First-line Systemic Therapy for Hormone Receptor-positive HER2-negative Metastatic Breast Cancer: A Trend Shift in the Era of CDK 4/6 Inhibitors.
Werutsky G; Reinert T; Rosa ML; Barrios CH
Clin Breast Cancer; 2021 Dec; 21(6):e688-e692. PubMed ID: 33992526
[TBL] [Abstract][Full Text] [Related]
19. Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.
Hao Y; Li N; Fang AP; Koo V; Peeples M; Kageleiry A; Wu EQ; Guérin A
Adv Ther; 2016 Jun; 33(6):983-97. PubMed ID: 27216253
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
